The project focuses on developing new experimental models of ovarian cancer that accurately reflect patients who do not respond to first-line platinum-based treatments and who are resistant to PARP inhibitors (PARPi). These models are essential for testing new drugs or drug combinations in preclinical settings that closely mimic real clinical conditions. These models will also help to identify predictive biomarkers of treatment response and to better understand the biological mechanisms behind therapy resistance.
Female patients with malignant ovarian gynecological disease.
Age 18 years or older.
Patients capable of providing informed consent.
None
Mario Negri Institute for Pharmacological Research
Lead sponsor
Istituto Europeo di Oncologia
Collaborator